Intravenously administered nanoparticles increase survival following blast trauma
Loading...
Links to Files
Author/Creator ORCID
Date
2014-07-15
Type of Work
Department
Program
Citation of Original Publication
Lashof-Sullivan, Margaret M., Erin Shoffstall, Kristyn T. Atkins, Nickolas Keane, Cynthia Bir, Pamela VandeVord, and Erin B. Lavik. "Intravenously Administered Nanoparticles Increase Survival Following Blast Trauma". Proceedings of the National Academy of Sciences 111, no. 28 (15 July 2014): 10293–98. https://doi.org/10.1073/pnas.1406979111.
Rights
This item is likely protected under Title 17 of the U.S. Copyright Law. Unless on a Creative Commons license, for uses protected by Copyright Law, contact the copyright holder or the author.
Subjects
Abstract
Explosions account for 79% of combat-related injuries, leading to multiorgan hemorrhage and uncontrolled bleeding. Uncontrolled bleeding is the leading cause of death in battlefield traumas as well as in civilian life. We need to stop the bleeding quickly to save lives, but, shockingly, there are no treatments to stop internal bleeding. A therapy that halts bleeding in a site-specific manner and is safe, stable at room temperature, and easily administered is critical for the advancement of trauma care. To address this need, we have developed hemostatic nanoparticles that are administered intravenously. When tested in a model of blast trauma with multiorgan hemorrhaging, i.v. administration of the hemostatic nanoparticles led to a significant improvement in survival over the short term (1 h postblast). No complications from this treatment were apparent out to 3 wk. This work demonstrates that these particles have the potential to save lives and fundamentally change trauma care.